首页 >
法规速递
-
Document: Classification of changes (tracked changes)-2025/12/3
2025-12-04查看详情 > -
Document: Nominations to the Network Portfolio Advisory Group-2026/1/7
2026-01-08查看详情 > -
关于将盐酸匹米替尼胶囊纳入“儿童抗肿瘤药物研发鼓励试点计划（星光计划）”试点项目的通知-2026/2/12
2026-02-13查看详情 > -
Page: Guidance and template on the risk management plan (RMP) for novel therapy veterinary medicinal products - Scientific guideline-2026/3/20
2026-03-23查看详情 > -
Document: Orientation guide for patient representatives and healthcare professionals - EMA building-2026/4/24
2026-04-27查看详情 > -
国家药监局关于修订间苯三酚注射剂说明书的公告（2022年第102号）-2022/11/11
2022-11-14查看详情 > -
国家药监局关于发布仿制药参比制剂目录（第六十六批）的通告（2023年第16号）-2023/03/15
2023-03-15查看详情 > -
Draft Guidance: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products-2023/9/21
2023-09-22查看详情 > -
Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2025-2025/1/6
2025-01-07查看详情 > -
Document: Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report - Variation-2025/2/11
2025-02-12查看详情 >
